Lomond Therapeutics Holdings, Inc. 8-K

What Happened

• Lomond Therapeutics Holdings, Inc. filed a Form 8-K (dated Jan 13, 2026) reporting that on January 8, 2026 it entered a Series A Preferred Unit Purchase Agreement and an Amended & Restated LLC Agreement to become an investor in Idwal Therapeutics, LLC. Lomond initially bought 3,103,448 Series A Preferred Units at $2.90 per unit for approximately $9.0 million, and holds an option to invest an additional ~ $2.0 million on the same terms. The closing occurred January 8, 2026.

Key Details

• 3,103,448 Series A Preferred Units purchased by Lomond at $2.90 each — aggregate ≈ $9.0 million.
• Lomond has an option to invest an additional ≈ $2.0 million on the same terms.
• Total Series A Preferred Units sold at closing: 16,206,893 for gross proceeds (cash and contributed assets) of ≈ $46,999,989.20.
• A&R LLC Agreement authorizes 18,064,512 Common Units and 16,896,548 Series A Preferred Units and sets the rights and governance for the Series A units.
• Initial managers of Idwal are Iain Dukes, Nikolay Savchuk, Carl Gordon and Eddie Wang Rodriguez — each is a member of Lomond’s board; Dr. Iain Dukes (Lomond CEO & Chairman) is the sole officer of Idwal.

Why It Matters

• This 8-K reports a material investment and governance stake by Lomond in a new entity (Idwal) that was formed with MALT‑1 program assets contributed by Tegid Therapeutics and outside investors. For Lomond investors, the filing signals a meaningful use of company capital (≈ $9M initially, plus an option for ≈ $2M more) and direct board-level involvement in Idwal’s management. The A&R LLC Agreement defines the economic and control terms for the new units; the full agreements are filed as exhibits to the 8‑K for review.